Arcutis posts pediatric PK results for topical roflumilast in plaque psoriasis
Arcutis Biotherapeutics reported results from a completed Phase 2 pediatric pharmacokinetics and safety study of ARQ-151 cream 0.3% (roflumilast) in children ages 2 to 5.
Arcutis had one item update this week, with results posted for a small pediatric psoriasis trial.
- ARQ-151-216, a Phase 2 open-label study of ARQ-151 cream 0.3% applied once daily for 4 weeks in pediatric subjects ages 2 to 5 years old with plaque psoriasis, sponsored by Arcutis Biotherapeutics1, is listed as completed with results posted. The study enrolled 10 participants1, and reported plasma concentrations of roflumilast at 2.15 ng/mL and 2.04 ng/mL at Weeks 2 and 4, respectively, one hour predose1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.